Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.
A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.
A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.
Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.
pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.
The Wilmer Eye Institute of Johns Hopkins Medicine in Baltimore (USA) announced today that it will collaborate in research, education and patient care with the King Khaled Eye Specialist Hospital in Riyadh (Saudi Arabia).
An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.
SoloHealth (www.solo-health.com), maker of EyeSite™ self-service vision testing and self-directed healthcare kiosks, has teamed with Atlanta area Kroger stores to promote eye health awareness and to encourage regular eye exams.
The incidence of diabetes continues to increase, particularly among adolescents and young adults. The CDC projects the number of diabetic retinopathy cases will double by 2050. On World Diabetes Day, November 14, the American Academy of Ophthalmology (Academy), through its EyeSmart™ campaign, is reminding the public that an annual dilated eye exam can help prevent vision loss in people with diabetes.
In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.
Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam.
Pan-American Association of Ophthalmology (PAAO) Joint Meeting, includes a Veterans Administration study that indicates that Iraq and Afghanistan veterans with vision loss from traumatic brain injury have significantly poorer quality of life than comparable civilian patients, and a Harvard doctor's insights on how to best evaluate and care for low-vision patients who experience vivid visual hallucinations due to Charles Bonnet syndrome.
pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien in patients with macular edema secondary to retinal vein occlusion.
In the blink of an eye, people at risk of becoming blind can now be screened for eye diseases such as diabetic retinopathy and age-related macular degeneration.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.
A team of scientists at the University of Oklahoma Health Sciences Center has created the first genetic research model for a microscopic part of the eye that when missing causes blindness. The research appears in a recent issue of the Journal of Biological Chemistry.
Some of the most serious health complications associated with diabetes could be prevented or delayed by taking a widely available cholesterol-lowering drug which has already been on the market for three decades, new research has shown.
A new technique that effectively delivers drugs to the eyes, using microscopic needles, could offer hope to the millions of patients worldwide suffering from common eye diseases that threaten vision such as glaucoma, macular degeneration and diabetic retinopathy.
A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.